ESC Congress 2026 Clinical Evidence Review: Seven Pivotal Trials, Guideline Updates, and AI Findings

This report distills the late-breaking and hot-line evidence from the European Society of Cardiology Congress held in Munich, 28–31 August 2026. It provides a side-by-side analysis of seven pivotal trials — CARDIO-TTRansform, ACACIA-HCM, LIBREXIA-ACS, SINGLE-AF, STAREE, PRESC1SE-MI, and CMR GUIDE — spanning ATTR cardiomyopathy, nonobstructive HCM, post-ACS antithrombotic therapy, atrial fibrillation stroke prevention, primary prevention in older adults, ED triage of suspected MI, and ICD-based primary prevention in intermediate-LVEF populations. Built around the underlying numbers, the report presents every trial's sample size, intervention, follow-up, primary endpoint effect estimate (HR/RR/OR with 95% CI and P value), and serious adverse-event profile. A benefit–risk classification grid, safety-signal visualizations, and five interpretive caveats — including the aficamten LVEF-reduction signal, the hypothesis-generating nature of the CARDIO-TTRansform subgroup finding, and the divergence between STAREE's two co-primary endpoints — help readers gauge evidence strength without being misled by isolated P values. Aimed at cardiologists, clinical researchers, and medical affairs and market-access teams, the report closes by clearly separating findings that are clinically actionable now (ACACIA-HCM, SINGLE-AF, STAREE cardiovascular endpoint, PRESC1SE-MI safety) from those that remain hypothesis-generating or non-confirmatory (CARDIO-TTRansform subgroup, LIBREXIA-ACS, CMR GUIDE). A high-density, decision-oriented reference to the strongest cardiovascular evidence out of ESC 2026.